Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli
• Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML.
Gespeichert in:
| Autor*in: |
Söderlund, Stina [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: N - Li, Danyang ELSEVIER, 2019, clinical and laboratory studies, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:50 ; year:2016 ; pages:95-103 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.leukres.2016.09.019 |
|---|
| Katalog-ID: |
ELV024184454 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV024184454 | ||
| 003 | DE-627 | ||
| 005 | 20230623173028.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.leukres.2016.09.019 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016003000008.pica |
| 035 | |a (DE-627)ELV024184454 | ||
| 035 | |a (ELSEVIER)S0145-2126(16)30211-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 333.7 |a 610 |q VZ |
| 084 | |a 43.12 |2 bkl | ||
| 084 | |a 43.13 |2 bkl | ||
| 084 | |a 44.13 |2 bkl | ||
| 100 | 1 | |a Söderlund, Stina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli |
| 264 | 1 | |c 2016 | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML. | ||
| 650 | 7 | |a Angiogenesis |2 Elsevier | |
| 650 | 7 | |a Tyrosine kinase inhibitor |2 Elsevier | |
| 650 | 7 | |a Proteomics |2 Elsevier | |
| 650 | 7 | |a Chronic myeloid leukemia |2 Elsevier | |
| 650 | 7 | |a Th1 |2 Elsevier | |
| 700 | 1 | |a Christiansson, Lisa |4 oth | |
| 700 | 1 | |a Persson, Inger |4 oth | |
| 700 | 1 | |a Hjorth-Hansen, Henrik |4 oth | |
| 700 | 1 | |a Richter, Johan |4 oth | |
| 700 | 1 | |a Simonsson, Bengt |4 oth | |
| 700 | 1 | |a Mustjoki, Satu |4 oth | |
| 700 | 1 | |a Olsson-Strömberg, Ulla |4 oth | |
| 700 | 1 | |a Loskog, Angelica |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Li, Danyang ELSEVIER |t N |d 2019 |d clinical and laboratory studies |g Amsterdam [u.a.] |w (DE-627)ELV002185202 |
| 773 | 1 | 8 | |g volume:50 |g year:2016 |g pages:95-103 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.leukres.2016.09.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-GGO | ||
| 936 | b | k | |a 43.12 |j Umweltchemie |q VZ |
| 936 | b | k | |a 43.13 |j Umwelttoxikologie |q VZ |
| 936 | b | k | |a 44.13 |j Medizinische Ökologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 50 |j 2016 |h 95-103 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
s s ss |
|---|---|
| matchkey_str |
sderlundstinachristianssonlisaperssoning:2016----:lsartoisnmptetbfradfeiiitootrsnknsihbtrhrprvasnuet1 |
| hierarchy_sort_str |
2016 |
| bklnumber |
43.12 43.13 44.13 |
| publishDate |
2016 |
| allfields |
10.1016/j.leukres.2016.09.019 doi GBVA2016003000008.pica (DE-627)ELV024184454 (ELSEVIER)S0145-2126(16)30211-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Söderlund, Stina verfasserin aut Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli 2016 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML. Angiogenesis Elsevier Tyrosine kinase inhibitor Elsevier Proteomics Elsevier Chronic myeloid leukemia Elsevier Th1 Elsevier Christiansson, Lisa oth Persson, Inger oth Hjorth-Hansen, Henrik oth Richter, Johan oth Simonsson, Bengt oth Mustjoki, Satu oth Olsson-Strömberg, Ulla oth Loskog, Angelica oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:50 year:2016 pages:95-103 extent:9 https://doi.org/10.1016/j.leukres.2016.09.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 50 2016 95-103 9 045F 610 |
| spelling |
10.1016/j.leukres.2016.09.019 doi GBVA2016003000008.pica (DE-627)ELV024184454 (ELSEVIER)S0145-2126(16)30211-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Söderlund, Stina verfasserin aut Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli 2016 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML. Angiogenesis Elsevier Tyrosine kinase inhibitor Elsevier Proteomics Elsevier Chronic myeloid leukemia Elsevier Th1 Elsevier Christiansson, Lisa oth Persson, Inger oth Hjorth-Hansen, Henrik oth Richter, Johan oth Simonsson, Bengt oth Mustjoki, Satu oth Olsson-Strömberg, Ulla oth Loskog, Angelica oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:50 year:2016 pages:95-103 extent:9 https://doi.org/10.1016/j.leukres.2016.09.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 50 2016 95-103 9 045F 610 |
| allfields_unstemmed |
10.1016/j.leukres.2016.09.019 doi GBVA2016003000008.pica (DE-627)ELV024184454 (ELSEVIER)S0145-2126(16)30211-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Söderlund, Stina verfasserin aut Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli 2016 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML. Angiogenesis Elsevier Tyrosine kinase inhibitor Elsevier Proteomics Elsevier Chronic myeloid leukemia Elsevier Th1 Elsevier Christiansson, Lisa oth Persson, Inger oth Hjorth-Hansen, Henrik oth Richter, Johan oth Simonsson, Bengt oth Mustjoki, Satu oth Olsson-Strömberg, Ulla oth Loskog, Angelica oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:50 year:2016 pages:95-103 extent:9 https://doi.org/10.1016/j.leukres.2016.09.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 50 2016 95-103 9 045F 610 |
| allfieldsGer |
10.1016/j.leukres.2016.09.019 doi GBVA2016003000008.pica (DE-627)ELV024184454 (ELSEVIER)S0145-2126(16)30211-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Söderlund, Stina verfasserin aut Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli 2016 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML. Angiogenesis Elsevier Tyrosine kinase inhibitor Elsevier Proteomics Elsevier Chronic myeloid leukemia Elsevier Th1 Elsevier Christiansson, Lisa oth Persson, Inger oth Hjorth-Hansen, Henrik oth Richter, Johan oth Simonsson, Bengt oth Mustjoki, Satu oth Olsson-Strömberg, Ulla oth Loskog, Angelica oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:50 year:2016 pages:95-103 extent:9 https://doi.org/10.1016/j.leukres.2016.09.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 50 2016 95-103 9 045F 610 |
| allfieldsSound |
10.1016/j.leukres.2016.09.019 doi GBVA2016003000008.pica (DE-627)ELV024184454 (ELSEVIER)S0145-2126(16)30211-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Söderlund, Stina verfasserin aut Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli 2016 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML. Angiogenesis Elsevier Tyrosine kinase inhibitor Elsevier Proteomics Elsevier Chronic myeloid leukemia Elsevier Th1 Elsevier Christiansson, Lisa oth Persson, Inger oth Hjorth-Hansen, Henrik oth Richter, Johan oth Simonsson, Bengt oth Mustjoki, Satu oth Olsson-Strömberg, Ulla oth Loskog, Angelica oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:50 year:2016 pages:95-103 extent:9 https://doi.org/10.1016/j.leukres.2016.09.019 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 50 2016 95-103 9 045F 610 |
| language |
English |
| source |
Enthalten in N Amsterdam [u.a.] volume:50 year:2016 pages:95-103 extent:9 |
| sourceStr |
Enthalten in N Amsterdam [u.a.] volume:50 year:2016 pages:95-103 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Umweltchemie Umwelttoxikologie Medizinische Ökologie |
| institution |
findex.gbv.de |
| topic_facet |
Angiogenesis Tyrosine kinase inhibitor Proteomics Chronic myeloid leukemia Th1 |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
N |
| authorswithroles_txt_mv |
Söderlund, Stina @@aut@@ Christiansson, Lisa @@oth@@ Persson, Inger @@oth@@ Hjorth-Hansen, Henrik @@oth@@ Richter, Johan @@oth@@ Simonsson, Bengt @@oth@@ Mustjoki, Satu @@oth@@ Olsson-Strömberg, Ulla @@oth@@ Loskog, Angelica @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV002185202 |
| dewey-sort |
3610 |
| id |
ELV024184454 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV024184454</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623173028.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.leukres.2016.09.019</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016003000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV024184454</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0145-2126(16)30211-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">333.7</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Söderlund, Stina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Angiogenesis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tyrosine kinase inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Proteomics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chronic myeloid leukemia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Th1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Christiansson, Lisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Persson, Inger</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hjorth-Hansen, Henrik</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richter, Johan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Simonsson, Bengt</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mustjoki, Satu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olsson-Strömberg, Ulla</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Loskog, Angelica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Li, Danyang ELSEVIER</subfield><subfield code="t">N</subfield><subfield code="d">2019</subfield><subfield code="d">clinical and laboratory studies</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV002185202</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:50</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:95-103</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.leukres.2016.09.019</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.13</subfield><subfield code="j">Umwelttoxikologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.13</subfield><subfield code="j">Medizinische Ökologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">50</subfield><subfield code="j">2016</subfield><subfield code="h">95-103</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Söderlund, Stina |
| spellingShingle |
Söderlund, Stina ddc 610 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier Angiogenesis Elsevier Tyrosine kinase inhibitor Elsevier Proteomics Elsevier Chronic myeloid leukemia Elsevier Th1 Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli |
| authorStr |
Söderlund, Stina |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV002185202 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 333 - Economics of land & energy |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli Angiogenesis Elsevier Tyrosine kinase inhibitor Elsevier Proteomics Elsevier Chronic myeloid leukemia Elsevier Th1 Elsevier |
| topic |
ddc 610 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier Angiogenesis Elsevier Tyrosine kinase inhibitor Elsevier Proteomics Elsevier Chronic myeloid leukemia Elsevier Th1 |
| topic_unstemmed |
ddc 610 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier Angiogenesis Elsevier Tyrosine kinase inhibitor Elsevier Proteomics Elsevier Chronic myeloid leukemia Elsevier Th1 |
| topic_browse |
ddc 610 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier Angiogenesis Elsevier Tyrosine kinase inhibitor Elsevier Proteomics Elsevier Chronic myeloid leukemia Elsevier Th1 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
l c lc i p ip h h h hhh j r jr b s bs s m sm u o s uos a l al |
| hierarchy_parent_title |
N |
| hierarchy_parent_id |
ELV002185202 |
| dewey-tens |
610 - Medicine & health 330 - Economics |
| hierarchy_top_title |
N |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV002185202 |
| title |
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli |
| ctrlnum |
(DE-627)ELV024184454 (ELSEVIER)S0145-2126(16)30211-9 |
| title_full |
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli |
| author_sort |
Söderlund, Stina |
| journal |
N |
| journalStr |
N |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
95 |
| author_browse |
Söderlund, Stina |
| container_volume |
50 |
| physical |
9 |
| class |
610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Söderlund, Stina |
| doi_str_mv |
10.1016/j.leukres.2016.09.019 |
| dewey-full |
610 333.7 |
| title_sort |
plasma proteomics in cml patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced th1 immunity and loss of angiogenic stimuli |
| title_auth |
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli |
| abstract |
• Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML. |
| abstractGer |
• Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML. |
| abstract_unstemmed |
• Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO |
| title_short |
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli |
| url |
https://doi.org/10.1016/j.leukres.2016.09.019 |
| remote_bool |
true |
| author2 |
Christiansson, Lisa Persson, Inger Hjorth-Hansen, Henrik Richter, Johan Simonsson, Bengt Mustjoki, Satu Olsson-Strömberg, Ulla Loskog, Angelica |
| author2Str |
Christiansson, Lisa Persson, Inger Hjorth-Hansen, Henrik Richter, Johan Simonsson, Bengt Mustjoki, Satu Olsson-Strömberg, Ulla Loskog, Angelica |
| ppnlink |
ELV002185202 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.leukres.2016.09.019 |
| up_date |
2024-07-06T20:45:25.155Z |
| _version_ |
1803863956030226432 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV024184454</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623173028.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.leukres.2016.09.019</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016003000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV024184454</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0145-2126(16)30211-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">333.7</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Söderlund, Stina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Angiogenesis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tyrosine kinase inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Proteomics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chronic myeloid leukemia</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Th1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Christiansson, Lisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Persson, Inger</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hjorth-Hansen, Henrik</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richter, Johan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Simonsson, Bengt</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mustjoki, Satu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olsson-Strömberg, Ulla</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Loskog, Angelica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Li, Danyang ELSEVIER</subfield><subfield code="t">N</subfield><subfield code="d">2019</subfield><subfield code="d">clinical and laboratory studies</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV002185202</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:50</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:95-103</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.leukres.2016.09.019</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.13</subfield><subfield code="j">Umwelttoxikologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.13</subfield><subfield code="j">Medizinische Ökologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">50</subfield><subfield code="j">2016</subfield><subfield code="h">95-103</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.398222 |